ArticlePharmacology research & perspectives2020

Phase I and pharmacokinetic study of the vascular-disrupting agent CKD-516 (NOV120401) in patients with refractory solid tumors.

Hark Kyun Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.